List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10955869/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Akt Stimulates Aerobic Glycolysis in Cancer Cells. Cancer Research, 2004, 64, 3892-3899.	0.9	1,297
2	18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Seminars in Nuclear Medicine, 2002, 32, 47-59.	4.6	495
3	Utility of FDG-PET scanning in lymphoma by WHO classification. Blood, 2003, 101, 3875-3876.	1.4	415
4	Positron Emission Tomography as a Diagnostic Tool in Infection: Present Role and Future Possibilities. Seminars in Nuclear Medicine, 2009, 39, 36-51.	4.6	231
5	Diagnosis and Localization of Focal Congenital Hyperinsulinism by 18F-Fluorodopa PET Scan. Journal of Pediatrics, 2007, 150, 140-145.	1.8	214
6	Positron emission tomography imaging in nonmalignant thoracic disorders. Seminars in Nuclear Medicine, 2002, 32, 293-321.	4.6	203
7	Functional Imaging of Inflammatory Diseases Using Nuclear Medicine Techniques. Seminars in Nuclear Medicine, 2009, 39, 124-145.	4.6	199
8	Electrical Stimulation Induces the Level of TGF-β1 mRNA in Osteoblastic Cells by a Mechanism Involving Calcium/Calmodulin Pathway. Biochemical and Biophysical Research Communications, 1997, 237, 225-229.	2.1	182
9	Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 1639-1647.	6.4	168
10	Role of Modern Imaging Techniques for Diagnosis of Infection in the Era of ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography. Clinical Microbiology Reviews, 2008, 21, 209-224.	13.6	166
11	Exclusion of Chronic Osteomyelitis With F-18 Fluorodeoxyglucose Positron Emission Tomographic Imaging. Clinical Nuclear Medicine, 2000, 25, 281-284.	1.3	161
12	Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders. Radiologic Clinics of North America, 2005, 43, 121-134.	1.8	157
13	18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. Journal of Nuclear Medicine, 2004, 45, 2058-62.	5.0	149
14	When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET?. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 779-787.	6.4	148
15	Potential role of FDG PET in the setting of diabetic neuro-osteoarthropathy: can it differentiate uncomplicated Charcot's neuroarthropathy from osteomyelitis and soft-tissue infection?. Nuclear Medicine Communications, 2007, 28, 465-472.	1.1	138
16	Rapid normalization of osseous FDG uptake following traumatic or surgical fractures. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1096-1103.	6.4	134
17	Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. Journal of Nuclear Medicine, 2005, 46, 1819-24.	5.0	134
18	Accuracy of [18F]Fluorodopa Positron Emission Tomography for Diagnosing and Localizing Focal Congenital Hyperinsulinism. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4706-4711.	3.6	132

#	Article	IF	CITATIONS
19	Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Seminars in Nuclear Medicine, 2004, 34, 313-329.	4.6	130
20	Persistent non-specific FDG uptake on PET imaging following hip arthroplasty. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 1328-1333.	6.4	119
21	FDG Positron Emission Tomography in the Surveillance of Hepatic Tumors Treated with Radiofrequency Ablation. Clinical Nuclear Medicine, 2003, 28, 192-197.	1.3	119
22	Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. Journal of Nuclear Medicine, 2006, 47, 1440-6.	5.0	117
23	Dual-Time Point FDG PET Imaging in the Evaluation of Pulmonary Nodules With Minimally Increased Metabolic Activity. Clinical Nuclear Medicine, 2007, 32, 101-105.	1.3	109
24	FDG-PET Imaging Can Diagnose Periprosthetic Infection of the Hip. Clinical Orthopaedics and Related Research, 2008, 466, 1338-1342.	1.5	98
25	FDG-PET Imaging in Primary Bilateral Adrenal Lymphoma: A Case Report and Review of the Literature. Clinical Nuclear Medicine, 2005, 30, 222-230.	1.3	96
26	Comparison of Fluorodeoxyglucose Positron Emission Tomography and 111Indium–White Blood Cell Imaging in the Diagnosis of Periprosthetic Infection of the Hip. Journal of Arthroplasty, 2006, 21, 91-97.	3.1	92
27	Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1469-1476.	6.4	89
28	Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma?. Journal of Nuclear Medicine, 2004, 45, 1323-7.	5.0	89
29	F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas. Pediatric Radiology, 2006, 36, 524-531.	2.0	87
30	Incidental Detection of Colon Cancer by FDG Positron Emission Tomography in Patients Examined for Pulmonary Nodules. Clinical Nuclear Medicine, 2002, 27, 628-632.	1.3	82
31	68Ga DOTATATE PET/CT is an Accurate Imaging Modality in the Detection of Culprit Tumors Causing Osteomalacia. Clinical Nuclear Medicine, 2015, 40, 642-646.	1.3	80
32	FDG PET for Diagnosing Infection in Hip and Knee Prostheses. Clinical Nuclear Medicine, 2014, 39, 609-615.	1.3	77
33	Evaluation of recurrent squamous cell carcinoma of the head and neck with FDG positron emission tomography. Clinical Nuclear Medicine, 2001, 26, 131-135.	1.3	74
34	Implications of PET based molecular imaging on the current and future practice of medicine. Seminars in Nuclear Medicine, 2004, 34, 56-69.	4.6	70
35	Mechanical Strain-Induced Proliferation of Osteoblastic Cells Parallels Increased TGF-β1 mRNA. Biochemical and Biophysical Research Communications, 1996, 229, 449-453.	2.1	69
36	Sarcoidosis Demonstrated by FDG PET Imaging With Negative Findings on Gallium Scintigraphy. Clinical Nuclear Medicine, 2005, 30, 193-195.	1.3	67

#	Article	IF	CITATIONS
37	Accuracy of PET/CT Scan in the diagnosis of the focal form of congenital hyperinsulinism. Journal of Pediatric Surgery, 2013, 48, 388-393.	1.6	65
38	lmaging in vivo herpes simplex virus thymidine kinase gene transfer to tumour-bearing rodents using positron emission tomography and [18F]FHPG. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 5-12.	2.1	59
39	Fluorodeoxyglucose-PET in characterizing solitary pulmonary nodules, assessing pleural diseases, and the initial staging, restaging, therapy planning, and monitoring response of lung cancer. Radiologic Clinics of North America, 2005, 43, 1-21.	1.8	59
40	18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas. Journal of Nuclear Medicine, 2004, 45, 1796-803.	5.0	56
41	81-Fluorodeoxyglucose Positron Emission Tomography as a Novel Imaging Tool for the Diagnosis of Aortoenteric Fistula and Aortic Graft Infection. Vascular and Endovascular Surgery, 2003, 37, 363-366.	0.7	54
42	Paraneoplastic Encephalitis Associated With Cystic Teratoma Is Detected by Fluorodeoxyglucose Positron Emission Tomography With Negative Magnetic Resonance Image Findings. Clinical Nuclear Medicine, 2003, 28, 893-896.	1.3	53
43	Diffuse Bone Marrow Accumulation of FDG in a Patient With Chronic Myeloid Leukemia Mimics Hematopoietic Cytokine-Mediated FDG Uptake on Positron Emission Tomography. Clinical Nuclear Medicine, 2004, 29, 637-639.	1.3	53
44	Safety and efficacy of tandem ¹³¹ lâ€metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma. Pediatric Blood and Cancer, 2011, 57, 1124-1129.	1.5	53
45	Diffuse Bone Marrow Involvement of Hodgkin Lymphoma Mimics Hematopoietic Cytokine-Mediated FDG uptake on FDG PET Imaging. Clinical Nuclear Medicine, 2003, 28, 674-676.	1.3	52
46	Standardized Uptake Values of Normal Breast Tissue with 2-Deoxy-2-[F-18]Fluoro-d-glucose Positron Emission Tomography: Variations with Age, Breast Density, and Menopausal Status. Molecular Imaging and Biology, 2006, 8, 355-362.	2.6	49
47	Quantification in PET. Radiologic Clinics of North America, 2004, 42, 1055-1062.	1.8	48
48	PET: a revolution in medical imaging. Radiologic Clinics of North America, 2004, 42, 983-1001.	1.8	48
49	Growing applications of FDG PET-CT imaging in non-oncologic conditions. Journal of Biomedical Research, 2015, 29, 189.	1.6	48
50	Effective detection of the tumors causing osteomalacia using [Tc-99m]-HYNIC-octreotide (99mTc-HYNIC-TOC) whole body scan. European Journal of Radiology, 2013, 82, 2028-2034.	2.6	46
51	Radiation-Induced Esophagitis on FDG PET Imaging. Clinical Nuclear Medicine, 2003, 28, 849-850.	1.3	45
52	SPECT/CT MIBG Imaging Is Crucial in the Follow-up of the Patients With High-Risk Neuroblastoma. Clinical Nuclear Medicine, 2018, 43, 232-238.	1.3	44
53	Catheter-Related Focal FDG Activity on Whole Body PET Imaging. Clinical Nuclear Medicine, 2004, 29, 238-242.	1.3	43
54	Value of ¹⁸ F-fluoro-2-deoxy- <scp>d</scp> -glucose positron emission tomography/computed tomography scan versus diagnostic contrast computed tomography in initial staging of pediatric patients with lymphoma. Leukemia and Lymphoma, 2013, 54, 737-742.	1.3	43

#	Article	IF	CITATIONS
55	latrogenic Artifacts on Whole-Body F-18 FDG PET Imaging. Clinical Nuclear Medicine, 2004, 29, 429-439.	1.3	41
56	Intense Fluorodeoxyglucose Activity in Pulmonary Amyloid Lesions on Positron Emission Tomography. Clinical Nuclear Medicine, 2003, 28, 975-976.	1.3	39
57	Demonstration of Increased FDC Activity in Rosai-Dorfman Disease on Positron Emission Tomography. Clinical Nuclear Medicine, 2004, 29, 209-210.	1.3	39
58	Prognostic Implication of Dual-Phase PET in Adenocarcinoma of the Lung. Journal of Nuclear Medicine, 2010, 51, 535-542.	5.0	39
59	Normal variants in [18F]-fluorodeoxyglucose PET imaging. Radiologic Clinics of North America, 2004, 42, 1063-1081.	1.8	38
60	^{99m} Tc-HYNIC-TOC Scintigraphy Is Superior to ¹³¹ I-MIBG Imaging in the Evaluation of Extraadrenal Pheochromocytoma. Journal of Nuclear Medicine, 2009, 50, 397-400.	5.0	38
61	Prevalence of Stress Reaction in the Pars Interarticularis in Pediatric Patients With New-Onset Lower Back Pain. Clinical Nuclear Medicine, 2013, 38, 110-114.	1.3	37
62	Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma?. Nuclear Medicine Communications, 2006, 27, 11-15.	1.1	36
63	Tc-99m Sulfur Colloid and Tc-99m Tagged Red Blood Cell Methods Are Comparable for Detecting Lower Gastrointestinal Bleeding in Clinical Practice. Clinical Nuclear Medicine, 2002, 27, 405-409.	1.3	34
64	Biodistribution of post-therapeutic versus diagnostic131I-MIBG scans in children with neuroblastoma. Pediatric Blood and Cancer, 2004, 42, 268-274.	1.5	33
65	Intense Esophageal FDG Activity Caused by Candida Infection Obscured the Concurrent Primary Esophageal Cancer on PET Imaging. Clinical Nuclear Medicine, 2005, 30, 695-697.	1.3	33
66	Demonstration of Excessive Metabolic Activity of Thoracic and Abdominal Muscles on FDG-PET in Patients With Chronic Obstructive Pulmonary Disease. Clinical Nuclear Medicine, 2005, 30, 159-164.	1.3	33
67	Comparison of I-123 and I-131 for Whole-Body Imaging After Stimulation by Recombinant Human Thyrotropin. Clinical Nuclear Medicine, 2003, 28, 93-96.	1.3	32
68	Facet Joint Arthropathy Demonstrated on FDG-PET. Clinical Nuclear Medicine, 2006, 31, 418-419.	1.3	32
69	Comparison of FDG-PET, MRI and CT for post radiofrequency ablation evaluation of hepatic tumors. Annals of Nuclear Medicine, 2013, 27, 58-64.	2.2	32
70	An update on the role of F-FDG-PET/CT in major infectious and inflammatory diseases. American Journal of Nuclear Medicine and Molecular Imaging, 2019, 9, 255-273.	1.0	32
71	Unsuspected Synchronous Lung Cancer Unveiled on FDG PET After Chemotherapy for Non-Hodgkin Lymphoma. Clinical Nuclear Medicine, 2008, 33, 109-110.	1.3	31
72	Potential False-Positive FDG PET Imaging Caused by Subcutaneous Radiotracer Infiltration. Clinical Nuclear Medicine, 2003, 28, 786-788.	1.3	30

#	Article	lF	CITATIONS
73	Chronic Cholecystitis Detected by FDG-PET. Clinical Nuclear Medicine, 2004, 29, 496-497.	1.3	30
74	Finding infection—help from PET. Lancet, The, 2001, 358, 1386.	13.7	29
75	Imaging of Lower Extremity Artery Atherosclerosis in Diabetic Foot. Clinical Nuclear Medicine, 2007, 32, 567-568.	1.3	29
76	Standardized Uptake Value as an Unreliable Index of Renal Disease on Fluorodeoxyglucose PET Imaging. Clinical Nuclear Medicine, 2000, 25, 358-360.	1.3	29
77	Investigation of thyroid, head, and neck cancers with PET. Radiologic Clinics of North America, 2004, 42, 1101-1111.	1.8	28
78	Radiation Myelopathy Visualized as Increased FDG Uptake on Positron Emission Tomography. Clinical Nuclear Medicine, 2005, 30, 560.	1.3	28
79	Critical Role of 18F-Labeled Fluorodeoxyglucose PET in the Management of Patients with Arthroplasty. Radiologic Clinics of North America, 2007, 45, 711-718.	1.8	28
80	I-131 MIBC post-therapy scan is more sensitive than I-123 MIBG pretherapy scan in the evaluation of metastatic neuroblastoma. Nuclear Medicine Communications, 2012, 33, 1134-1137.	1.1	28
81	Detection of Chronic Recurrent Lower Extremity Deep Venous Thrombosis on Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography. Clinical Nuclear Medicine, 2000, 25, 838-839.	1.3	27
82	Acute Bronchitis Imaged with F-18 FDG Positron Emission Tomography. Clinical Nuclear Medicine, 2003, 28, 511-512.	1.3	25
83	Diffuse FDG Uptake in the Lungs in Aspiration Pneumonia on Positron Emission Tomographic Imaging. Clinical Nuclear Medicine, 2004, 29, 567-568.	1.3	24
84	Minimal Lymphatic Leakage in an Infant With Chylothorax Detected by Lymphoscintigraphy SPECT/CT. Pediatrics, 2014, 134, e606-e610.	2.1	24
85	Increased Tc-99m MDP Accumulation in Soft Tissue Caused by Bicycle Riding. Clinical Nuclear Medicine, 2004, 29, 279-280.	1.3	22
86	Detection of Bone Marrow Metastases by FDG-PET and Missed by Bone Scintigraphy in Widespread Melanoma. Clinical Nuclear Medicine, 2005, 30, 606-607.	1.3	22
87	Comparison of methods of quantifying global synovial metabolic activity with FDGâ€PET/CT in rheumatoid arthritis. International Journal of Rheumatic Diseases, 2019, 22, 2191-2198.	1.9	22
88	Achilles Tendonitis Detected by FDG-PET. Clinical Nuclear Medicine, 2006, 31, 147-148.	1.3	21
89	Diffuse Hepatic and Splenic Uptake of Tc-99m Methylene Diphosphonate on Bone Scintigraphy After Intravenous Administration of Gadolinium-Containing MRI Contrast. Clinical Nuclear Medicine, 2011, 36, 178-182.	1.3	21
90	Elevated Iodine Uptake at Autogenous Bone Graft Harvest Sites. Clinical Nuclear Medicine, 2012, 37, 901-903.	1.3	21

#	Article	IF	CITATIONS
91	Osteomalacia-Inducing Renal Clear Cell Carcinoma Uncovered by 99mTc-Hydrazinonicotinyl-Tyr3-Octreotide (99mTc-HYNIC-TOC) Scintigraphy. Clinical Nuclear Medicine, 2013, 38, 922-924.	1.3	21
92	Radionuclide Salivagram and Gastroesophageal Reflux Scintigraphy in Pediatric Patients. Clinical Nuclear Medicine, 2015, 40, 559-563.	1.3	21
93	Quantitative evaluation of normal spinal osseous metabolism with 18F-NaF PET/CT. Nuclear Medicine Communications, 2018, 39, 945-950.	1.1	21
94	Mild-to-moderate hyperglycemia will not decrease the sensitivity of 18F-FDG PET imaging in the detection of pedal osteomyelitis in diabetic patients. Nuclear Medicine Communications, 2016, 37, 259-262.	1.1	21
95	Gastric Distension by Ingesting Food Is Useful in the Evaluation of Primary Gastric Cancer by FDG PET. Clinical Nuclear Medicine, 2007, 32, 106-109.	1.3	20
96	Cardiac Pheochromocytomas Detected by Tc-99m-Hydrazinonicotinyl-Tyr3-Octreotide (HYNIC-TOC) Scintigraphy. Clinical Nuclear Medicine, 2007, 32, 182-185.	1.3	20
97	Elevated FDG Activity in the Spinal Cord and the Sciatic Nerves Due to Neuropathy. Clinical Nuclear Medicine, 2009, 34, 950-951.	1.3	20
98	Lung Sequestration and Pott Disease Masquerading as Primary Lung Cancer With Bone Metastases on FDG PET/CT. Clinical Nuclear Medicine, 2009, 34, 236-238.	1.3	20
99	Intense F-18 fluorodeoxyglucose uptake caused by mycobacterium avium intracellulare infection. Clinical Nuclear Medicine, 2001, 26, 458.	1.3	19
100	Dual Time Point C-11 Acetate PET Imaging Can Potentially Distinguish Focal Nodular Hyperplasia From Primary Hepatocellular Carcinoma. Clinical Nuclear Medicine, 2009, 34, 874-877.	1.3	19
101	99mTc-HYNIC-TOC (99mTc-Hydrazinonicotinyl-Tyr3-Octreotide) Scintigraphy Identifying Two Separate Causative Tumors in a Patient With Tumor-Induced Osteomalacia (TIO). Clinical Nuclear Medicine, 2013, 38, 664-667.	1.3	19
102	Varicella Zoster Infection Associated Rhabdomyolysis Demonstrated by Tc-99m MDP Imaging. Clinical Nuclear Medicine, 2003, 28, 594-595.	1.3	18
103	Age-related decrease in cardiopulmonary adrenergic neuronal function in children as assessed by I-123 metaiodobenzylguanidine imaging. Journal of Nuclear Cardiology, 2008, 15, 73-79.	2.1	18
104	Hepatic Paragonimiasis Revealed by FDG PET/CT. Clinical Nuclear Medicine, 2010, 35, 726-728.	1.3	18
105	Non-Hodgkin's lymphoma of the bone and the liver without lymphadenopathy revealed on FDG-PET/CT. Clinical Imaging, 2010, 34, 476-479.	1.5	18
106	Spontaneous Regression of Follicular, Mantle Cell, and Diffuse Large B-Cell Non-Hodgkin's Lymphomas Detected by FDG–PET Imaging. Clinical Nuclear Medicine, 2004, 29, 685-688.	1.3	17
107	FDC PET imaging for diagnosing prosthetic joint infection: discussing the facts, rectifying the unsupported claims and call for evidence-based and scientific approach. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 464-466.	6.4	17
108	Intense lodine Activity Caused by Mosquito Bite. Clinical Nuclear Medicine, 2013, 38, e414-e416.	1.3	17

#	Article	IF	CITATIONS
109	MIBG Activity in the Gallbladder. Clinical Nuclear Medicine, 2016, 41, 576-577.	1.3	17
110	Chest Tube Insertion as a Potential Source of False-Positive FDG–Positron Emission Tomographic Results. Clinical Nuclear Medicine, 2002, 27, 285-286.	1.3	17
111	Clinical Significance of Incidental Focal Versus Diffuse Thyroid Uptake on FDG-PET Imaging. PET Clinics, 2007, 2, 321-329.	3.0	16
112	FDG PET and PET/CT Imaging in Complicated Diabetic Foot. PET Clinics, 2012, 7, 151-160.	3.0	16
113	Persistent Intense MIBG Activity in the Liver Caused by Prior Radiation. Clinical Nuclear Medicine, 2014, 39, 926-930.	1.3	16
114	Relationship Between the Elevated Muscle FDG Uptake in the Distal Upper Extremities on PET/CT Scan and Prescan Utilization of Mobile Devices in Young Patients. Clinical Nuclear Medicine, 2018, 43, 168-173.	1.3	16
115	Similar Pelvic Abnormalities on FDG Positron Emission Tomography of Different Origins. Clinical Nuclear Medicine, 2001, 26, 515-517.	1.3	15
116	Rosai-Dorfman Disease Mimics Lymphoma on FDG PET/CT in a Pediatric Patient. Clinical Nuclear Medicine, 2014, 39, 206-208.	1.3	15
117	Diffuse Elevated MIBC Activity in the Renal Parenchyma Caused by Compromised Renal Blood Flow. Clinical Nuclear Medicine, 2014, 39, 1005-1008.	1.3	15
118	Multiple FDC-Avid Injection Site Granulomas Due to Lovenox Injection. Clinical Nuclear Medicine, 2014, 39, 308-311.	1.3	15
119	Long-Lasting FDG Uptake in the Muscles After Strenuous Exercise. Clinical Nuclear Medicine, 2015, 40, 975-976.	1.3	15
120	Increased MIBG Activity in the Uterine Cervix Due to Menstruation. Clinical Nuclear Medicine, 2015, 40, 179-181.	1.3	14
121	Comparison of 18F-sodium fluoride uptake in the whole bone, pelvis, and femoral neck of multiple myeloma patients before and after high-dose therapy and conventional-dose chemotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2846-2855.	6.4	14
122	Detection of cranial metastases by F-18 FDG positron emission tomography. Clinical Nuclear Medicine, 2001, 26, 402-404.	1.3	13
123	Transiently Increased MDP Activity in the Soft Tissue of Lower Extremity Caused by Iliofemoral Venous Thrombosis. Clinical Nuclear Medicine, 2005, 30, 742-743.	1.3	13
124	Intussusception incidentally detected by FDG-PET/CT in a pediatric lymphoma patient. Annals of Nuclear Medicine, 2010, 24, 555-558.	2.2	13
125	Neuroblastoma with a Solitary Intraventricular Brain Metastasis Visualized on Iâ€123 MIBG Scan. Journal of Neuroimaging, 2014, 24, 202-204.	2.0	13
126	Malignant Lesions Can Mimic Gastric Uptake on FDG PET. Clinical Nuclear Medicine, 2006, 31, 37-38.	1.3	12

#	Article	IF	CITATIONS
127	Non-Hodgkin's Lymphoma of the Bone Can Mimic Osteomyelitis on FDG PET. Clinical Nuclear Medicine, 2007, 32, 252-254.	1.3	12
128	FDG PET and PET/CT in the Management of Pediatric Lymphoma Patients. PET Clinics, 2008, 3, 621-634.	3.0	12
129	Elevated MDP Activity in the Spleen Due to Fungal Infection. Clinical Nuclear Medicine, 2011, 36, 811-813.	1.3	12
130	Tube Feeding Increases the Gastric-Emptying Rate Determined by Gastroesophageal Scintigraphy. Clinical Nuclear Medicine, 2013, 38, 962-965.	1.3	12
131	Acute Lymphocytic Leukemia Presented as Back Pain and Revealed by Bone Scintigraphy. Clinical Nuclear Medicine, 2013, 38, 649-651.	1.3	12
132	Limbus Vertebra on Bone Scintigraphy in a Pediatric Patient. Clinical Nuclear Medicine, 2015, 40, 915-916.	1.3	12
133	Focally Increased MIBG Activity in the Muscle. Clinical Nuclear Medicine, 2016, 41, 167-168.	1.3	12
134	Evolving Role of MR Imaging and PET in Assessing Osteoporosis. PET Clinics, 2019, 14, 31-41.	3.0	12
135	Isolated cholangiolitis revealed by 18F-FDG-PET/CT in a patient with fever of unknown origin. Hellenic Journal of Nuclear Medicine, 2011, 14, 60-1.	0.3	12
136	Hodgkin Disease in the Sinonasal Region Detected by FDG PET. Clinical Nuclear Medicine, 2004, 29, 449.	1.3	11
137	Cytomegalovirus Pneumonitis Detected by Gallium-67 Scintigraphy With a Negative Diagnostic Chest Computed Tomography. Clinical Nuclear Medicine, 2010, 35, 542-544.	1.3	11
138	Earlier Detection of Bone Metastases From Pleomorphic Liposarcoma in a Pediatric Patient by FDG PET/CT Than Planar 99mTc MDP Bone Scan. Clinical Nuclear Medicine, 2012, 37, e104-e107.	1.3	11
139	Disparities in Uptake Pattern of 123I-MIBC, 18F-FDC, and 99mTc-MDP Within the Same Primary Neuroblastoma. Clinical Nuclear Medicine, 2014, 39, e184-e186.	1.3	11
140	Non-Hodgkin Lymphoma Dominated by Multiple Organ Extranodal Disease Revealed on FDG PET/CT. Clinical Nuclear Medicine, 2015, 40, 360-363.	1.3	11
141	Metastatic Embryonal Rhabdomyosarcoma to the Pancreas Presenting as Acute Pancreatitis Detected by FDG PET/CT. Clinical Nuclear Medicine, 2012, 37, 694-696.	1.3	10
142	Asymmetric Thoracic Metaiodobenzylguanidine (MIBG) Activity Due to Prior Radiation Therapy. Clinical Nuclear Medicine, 2015, 40, e338-e340.	1.3	10
143	Variable MIBG Activity in the Same Renal Cyst. Clinical Nuclear Medicine, 2017, 42, 887-889.	1.3	10
144	An Isolated Osseous Rosai-Dorfman Disease Shown on FDG PET/CT. Clinical Nuclear Medicine, 2019, 44, 485-488.	1.3	10

#	Article	IF	CITATIONS
145	Burkitt's Lymphoma Involving Multiple Hormone-Producing Organs on FDG PET/CT. Clinical Nuclear Medicine, 2019, 44, 995-997.	1.3	10
146	Detection of Barrett's Esophagus Superimposed by Esophageal Cancer by FDG Positron Emission Tomography. Clinical Nuclear Medicine, 2001, 26, 1060.	1.3	10
147	Similar Findings on 18F-MFBG PET/CT and 68Ga-DOTATATE PET/CT in a Patient With Widespread Metastatic Pheochromocytoma. Clinical Nuclear Medicine, 2022, 47, 451-453.	1.3	10
148	Applications of PET/CT in Pediatric Patients with Fever of Unknown Origin. PET Clinics, 2008, 3, 605-619.	3.0	9
149	Relation Between Popliteal-Tibial Artery Atherosclerosis and Global Glycolytic Metabolism in the Affected Diabetic Foot. Journal of the American Podiatric Medical Association, 2012, 102, 240-246.	0.3	9
150	Hepatocelluar Carcinoma in an Accessory Lobe of the Liver Revealed by 11C-Acetate PET With a Negative Finding on FDG Imaging. Clinical Nuclear Medicine, 2012, 37, 393-395.	1.3	9
151	Abnormal FDG and MIBG Activity in the Bones in a Patient With Neuroblastoma Without Detectable Primary Tumor. Clinical Nuclear Medicine, 2016, 41, 632-633.	1.3	9
152	Increased Gastric MIBG Activity as a Normal Variant. Clinical Nuclear Medicine, 2019, 44, 761-763.	1.3	9
153	Roles of PET/Computed Tomography in the Evaluation of Neuroblastoma. PET Clinics, 2020, 15, 321-331.	3.0	9
154	Fever of Unknown Origin: The Roles of FDG PET or PET/CT. PET Clinics, 2012, 7, 181-189.	3.0	8
155	FDG PET/CT Findings of the Recurrent Posttransplantation Lymphoproliferative Disorder in a Pediatric Liver Transplant Recipient With Right Leg Pain as the Only Complaint. Clinical Nuclear Medicine, 2015, 40, 832-834.	1.3	8
156	Dumbbell-Shaped Activity on Meckel's Scintigraphy Caused by Hiatal Hernia. Clinical Nuclear Medicine, 2016, 41, 387-389.	1.3	8
157	FDG Accumulation in the Lumen of the Gallbladder Without Related Pathology. Clinical Nuclear Medicine, 2018, 43, 383-385.	1.3	8
158	Pulmonary Clostridium perfringens Infection Detected by FDG Positron Emission Tomography. Clinical Nuclear Medicine, 2003, 28, 517-518.	1.3	7
159	Fluorodeoxyglucose Positron Emission Tomography Excludes Pericardial Metastasis by Recurrent Lung Cancer. Clinical Nuclear Medicine, 2003, 28, 666-667.	1.3	7
160	Application of 18F-Fluorodeoxyglucose and PET in Evaluation of the Diabetic Foot. PET Clinics, 2006, 1, 123-130.	3.0	7
161	Beware of Mosquitoes: The First Instance of a Mosquito Bite Detected by Fluorodeoxyglucose Positron Emission Tomography. Pediatric Dermatology, 2007, 24, 344-345.	0.9	7
162	FDG PET Assessment of Osteomyelitis: A Review. PET Clinics, 2012, 7, 161-179.	3.0	7

#	Article	IF	CITATIONS
163	Bone Marrow Metastases From Alveolar Rhabdomyosarcoma With Impressive FDG PET/CT Finding But Less-Revealing Bone Scintigraphy. Clinical Nuclear Medicine, 2013, 38, 988-991.	1.3	7
164	A Large Pelvic Soft Tissue Mass Implied by Subtle Bone Scan Findings. Clinical Nuclear Medicine, 2014, 39, 402-405.	1.3	7
165	Constipation Causing Elevated Iodine Activity in the Rectum Mimicking Thyroid Cancer Metastases. Clinical Nuclear Medicine, 2015, 40, 442-445.	1.3	7
166	Primary Neuroblastoma Involving Spinal Canal. Clinical Nuclear Medicine, 2016, 41, 986-988.	1.3	7
167	Elevated MIBG Activity at the Site of Erythema of Unknown Etiology. Clinical Nuclear Medicine, 2017, 42, 227-230.	1.3	7
168	Acrometastasis of Neuroblastoma to the Great Toe Revealed by MIBG Scan. Clinical Nuclear Medicine, 2017, 42, 397-400.	1.3	7
169	¹⁸ F-6-Fluoro-l-Dopa PET/CT Imaging of Congenital Hyperinsulinism. Journal of Nuclear Medicine, 2021, 62, 51S-56S.	5.0	7
170	Horseshoe Kidney on FDG Positron Emission Tomographic Imaging Is Easily Confused with Malignancy. Clinical Nuclear Medicine, 2001, 26, 351-352.	1.3	7
171	Pelvic Kidney Mimicking Recurrent Colon Cancer on FDG Positron Emission Tomographic Imaging. Clinical Nuclear Medicine, 2002, 27, 602-603.	1.3	7
172	Hiatal Hernia Mimics Centrally Necrotic Cancer in the Lung on FDG Positron Emission Tomographic Imaging. Clinical Nuclear Medicine, 2003, 28, 347-349.	1.3	6
173	Evaluating the Role of Fluorodeoxyglucose PET Imaging in the Management of Patients with Sarcoidosis. PET Clinics, 2006, 1, 141-152.	3.0	6
174	Follow-up FDG PET in the Evaluation of Unexplained Focal Activity in the Abdomen. Clinical Nuclear Medicine, 2008, 33, 19-22.	1.3	6
175	Intense Octreotide Activity in a Thrombus. Clinical Nuclear Medicine, 2008, 33, 140-141.	1.3	6
176	FDG PET/CT Detection of Intussusception Caused by Aggressive Fibromatosis. Clinical Nuclear Medicine, 2010, 35, 370-373.	1.3	6
177	Rare Cerebral and Pulmonary Metastases From Low-Grade Basal Cell Adenocarcinoma of the Parotid Gland. Clinical Nuclear Medicine, 2011, 36, 1124-1126.	1.3	6
178	PET/CT in Patients with Sarcoidosis or IgG4 Disease. PET Clinics, 2012, 7, 191-210.	3.0	6
179	Acral Involvement of Lymphoblastic Lymphoma Revealed on FDG PET/CT. Clinical Nuclear Medicine, 2019, 44, 334-336.	1.3	6
180	Pre-treatment partial-volume-corrected TLG is the best predictor of overall survival in patients with relapsing/refractory non-hodgkin lymphoma following radioimmunotherapy. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 407-414.	1.0	6

#	Article	IF	CITATIONS
181	Value of 18-Fluoro-2-Deoxyglucose PET in the Management of Patients with Fever of Unknown Origin. PET Clinics, 2006, 1, 163-177.	3.0	5
182	Initial Diagnosis and Treatment Follow Up of Neuroblastoma Invasion of Inferior Vena Cava With I-123 Metaiodobenzylguanidine Scintigraphy. Clinical Nuclear Medicine, 2006, 31, 718-720.	1.3	5
183	Hepatobiliary Scintigraphy Monitoring Patency of Partial External Biliary Diversion in a Patient With Progressive Familial Intrahepatic Cholestasis. Clinical Nuclear Medicine, 2006, 31, 622-623.	1.3	5
184	Fluorine-18 DOPA-PET and PET/CT Imaging in Congenital Hyperinsulinism. PET Clinics, 2008, 3, 577-585.	3.0	5
185	Review of Clinical Applications of Fluorodeoxyglucose-PET/Computed Tomography in Pediatric Patients with Lymphoma. PET Clinics, 2012, 7, 47-56.	3.0	5
186	Brain Single-Photon Emission Computed Tomography in Fetal Alcohol Syndrome. Journal of Child Neurology, 2012, 27, 1580-1584.	1.4	5
187	Aspiration Incidentally Detected by a Meckel Scintigraphy. Clinical Nuclear Medicine, 2017, 42, 985-987.	1.3	5
188	Correlation of whole-bone marrow dual-time-point F-FDG, as measured by a CT-based method of PET/CT quantification, with response to treatment in newly diagnosed multiple myeloma patients. American Journal of Nuclear Medicine and Molecular Imaging, 2020, 10, 257-264.	1.0	5
189	The increased level of PDGFâ€A contributes to the increased proliferation induced by mechanical stimulation in osteoblastic cells. IUBMB Life, 1997, 43, 339-346.	3.4	4
190	Intercostal Muscle Contraction or Rib Bone Marrow Activity?. Clinical Nuclear Medicine, 2007, 32, 739-740.	1.3	4
191	Bone Scintigraphy for the Evaluation of Possible Osteomyelitis in the Lower Extremity Leads to the Detection of a Brain Abscess. Clinical Nuclear Medicine, 2008, 33, 711-712.	1.3	4
192	Applications of PET and PET/CT in the Evaluation of Infection and Inflammation in the Skeletal System. PET Clinics, 2010, 5, 375-385.	3.0	4
193	Absence of FDG Uptake in a Trauma Patient With Compromised Vasculature as Evidence of Tissue Nonviability. Clinical Nuclear Medicine, 2011, 36, 959-960.	1.3	4
194	Elevated Soft Tissue Activity in Early but not Delayed Phase of Bone Scan in Klippel-Trenaunay Syndrome. Clinical Nuclear Medicine, 2013, 38, 223-225.	1.3	4
195	Horseshoe Kidney Incidentally Revealed on Meckel Scintigraphy. Clinical Nuclear Medicine, 2015, 40, 742-743.	1.3	4
196	Persistent Asymmetric Brain MIBG Activity Related to a Cerebrovascular Infarct. Clinical Nuclear Medicine, 2016, 41, 344-345.	1.3	4
197	Neuroblastoma Presenting as Non–MIBG-Avid Widespread Soft Tissue Metastases Without Bone Involvement Revealed by FDG PET/CT Imaging. Clinical Nuclear Medicine, 2017, 42, 643-644.	1.3	4
198	Similar Appearance on Dynamic Images of Meckel Scintigraphy Caused by Different Etiologies. Clinical Nuclear Medicine, 2019, 44, 417-419.	1.3	4

#	Article	IF	CITATIONS
199	Pretreatment volumetric parameters of FDG-PET predict the survival after Yttrium-90 radio-embolization in metastatic liver disease. American Journal of Nuclear Medicine and Molecular Imaging, 2019, 9, 248-254.	1.0	4
200	Prognostic significance of F-sodium fluoride in newly diagnosed multiple myeloma patients. American Journal of Nuclear Medicine and Molecular Imaging, 2020, 10, 151-160.	1.0	4
201	Unrecognized Renal Transplants as a Potential Source of False-Positive Interpretation of FDG PET. Clinical Nuclear Medicine, 2003, 28, 655-657.	1.3	3
202	Ring-Shaped FDG Uptake in the Right Lower Lung: Is It Always a Tumor?. Clinical Nuclear Medicine, 2004, 29, 324-325.	1.3	3
203	Assessment of Therapy Response by Fluorine-18 Fluorodeoxyglucose PET in Infection and Inflammation. PET Clinics, 2006, 1, 191-198.	3.0	3
204	Positron Emission Tomography Imaging and Hyperinsulinism. PET Clinics, 2007, 2, 377-383.	3.0	3
205	Multimodality Imaging Assessment of Pulmonary Nodules. PET Clinics, 2011, 6, 231-250.	3.0	3
206	Promising Roles of PET in Management of Arthroplasty-Associated Infection. PET Clinics, 2012, 7, 139-150.	3.0	3
207	Assessment of Therapy Response by FDG PET in Infection and Inflammation. PET Clinics, 2012, 7, 233-243.	3.0	3
208	Heat-Damaged Red Blood Cell Scintigraphy in Helping Interpretation of 68Ga-DOTATATE PET/CT. Clinical Nuclear Medicine, 2019, 44, 927-928.	1.3	3
209	Evolving Role of PET in Pediatric Disorders. PET Clinics, 2020, 15, xv-xvii.	3.0	3
210	Elevated 68Ga-DOTATATE Activity in Fibrous Cortical Defect. Clinical Nuclear Medicine, 2020, 45, 417-419.	1.3	3
211	An Atypical Case of Meckel's Diverticulum Assessed by SPECT/CT Imaging. Clinical Nuclear Medicine, 2022, 47, 372-374.	1.3	3
212	How High Can the Standardized Uptake Value Be?. Clinical Nuclear Medicine, 2002, 27, 819.	1.3	2
213	Pelvic Horseshoe Kidney Mimics Sacral Metastases on Bone Scan. Clinical Nuclear Medicine, 2005, 30, 506-509.	1.3	2
214	PET and PET/CT in Pediatric Gastrointestinal Tract Oncology. PET Clinics, 2008, 3, 227-238.	3.0	2
215	Pediatric Cardiac PET Imaging. PET Clinics, 2008, 3, 587-596.	3.0	2
216	Varicose Vein as a Cause of Increased FDG Uptake. Clinical Nuclear Medicine, 2010, 35, 273-274.	1.3	2

#	Article	IF	CITATIONS
217	Two Primary Colon Cancers Shown on FDG PET/CT Performed to Evaluate Possible Lung Metastases From Bladder Cancer. Clinical Nuclear Medicine, 2010, 35, 53-54.	1.3	2
218	Diffuse Elevated Abdominal Activity on 99mTc-Labeled Red Blood Cell Imaging in a Pediatric Patient With Klippel Trenaunay Syndrome. Clinical Nuclear Medicine, 2016, 41, 899-901.	1.3	2
219	Inadvertent Arterial Injection of 123I-MIBG Does Not Necessarily Cause Any Symptoms. Clinical Nuclear Medicine, 2017, 42, 723-724.	1.3	2
220	Increased Activity in the Lung Field on Gastroesophageal Scintigraphy Is Not Always Due to Aspiration. Clinical Nuclear Medicine, 2017, 42, 719-720.	1.3	2
221	Congenital Penile Rhabdomyosarcoma on FDG PET/CT. Clinical Nuclear Medicine, 2018, 43, 852-853.	1.3	2
222	Unusual Focal Muscle FDG Activity Related to Altered Biomechanics. Clinical Nuclear Medicine, 2019, 44, 173-175.	1.3	2
223	Renal Metastasis From Neuroblastoma Shown on MIBG Imaging. Clinical Nuclear Medicine, 2020, 45, 87-89.	1.3	2
224	Therapy Response in a Pediatric Patient With Extracutaneous Juvenile Xanthogranuloma Monitored by FDG PET/CT. Clinical Nuclear Medicine, 2020, 45, 303-305.	1.3	2
225	Neuroblastoma Shown on 18F-DOPA PET/CT Performed to Evaluate Congenital Hyperinsulinism. Clinical Nuclear Medicine, 2021, 46, 927-928.	1.3	2
226	Ventral Hernia Resulting in Increased Fluorodeoxyglucose Uptake on Positron Emission Tomographic Imaging. Clinical Nuclear Medicine, 2002, 27, 920-921.	1.3	1
227	Title is missing!. Clinical Nuclear Medicine, 2003, 28, 655-657.	1.3	1
228	Critical Role of 18F-Labeled Fluorodeoxyglucose PET in the Management of Patients with Arthroplasty. PET Clinics, 2006, 1, 99-106.	3.0	1
229	Preface. PET Clinics, 2006, 1, xi-xvi.	3.0	1
230	What Resulted in the Radioactivity Superior to the Left Kidney on Renal Scintigraphy?. Clinical Nuclear Medicine, 2007, 32, 325-327.	1.3	1
231	Preface. PET Clinics, 2008, 3, xi-xii.	3.0	1
232	Elevated FDG Activity in the Nonpneumatized Sphenoid Bone in an Infant. Clinical Nuclear Medicine, 2017, 42, 798-800.	1.3	1
233	Hyperthyroidism Incidentally Noted on Lymphoscintigraphy. Clinical Nuclear Medicine, 2021, Publish Ahead of Print, 761-763.	1.3	1
234	Ectopic Gallbladder Mimicking Choledochal Cyst on Hepatobiliary Scintigraphy. Clinical Nuclear Medicine, 2020, 45, 471-473.	1.3	1

#	Article	IF	CITATIONS
235	The Heart or a Tumor?. Clinical Nuclear Medicine, 2003, 28, 146-149.	1.3	0
236	PET Imaging of Infection and Inflammation. PET Clinics, 2012, 7, xi.	3.0	0
237	Necessity of performing I-131 MIBG post-therapy scans in patients with metastatic neuroblastoma. Nuclear Medicine Communications, 2013, 34, 1023-1024.	1.1	0
238	Prominent Pulmonary Metastases Without Concurrent Osseous Involvement in Patients With High-Risk Neuroblastoma. Clinical Nuclear Medicine, 2017, 42, 534-536.	1.3	0
239	FDG PET/CT Findings of Nodular Sclerosis–Subtype Classic Hodgkin Lymphoma Presented as Mediastinal Nodal Lesions at Onset But as Predominant Osseous Disease at Relapse. Clinical Nuclear Medicine, 2017, 42, 496-498.	1.3	0
240	Semi-quantitative assessment optimized the grading of pulmonary aspiration on salivagram in children. Annals of Nuclear Medicine, 2021, 35, 321-327.	2.2	0
241	Impact of FDG-PET Imaging Versus Conventional Staging Modalities on Staging and Treatment Decisions in Large B-Cell, Follicular, and Hodgkin's Lymphomas Blood, 2004, 104, 4565-4565.	1.4	0
242	Evolving Role of FDG-PET Imaging in the Management of Patients with Suspected Infection and Inflammatory Disorders. , 2006, , 303-316.		0
243	Increased Genioglossus Muscle FDG Activity Due to Using Pacifier. Clinical Nuclear Medicine, 2022, Publish Ahead of Print, .	1.3	0
244	Ectopic Gallbladder in the Left Upper Abdomen Shown on Hepatobiliary Scintigraphy. Clinical Nuclear Medicine, 2022, Publish Ahead of Print, .	1.3	0